Pipeline

Advancing Novel T Cell Engaging Immunotherapies

Harpoon is a clinical-stage immuno-oncology company building a pipeline of wholly-owned immunotherapies harnessing the tumor-killing power of T cells for patients with difficult-to-treat tumors.

TriTAC

DLL3
Small Cell Lung Cancer
    
BCMA
Multiple Myeloma
    
MSLN
Ovarian Cancer & Other Solid Tumors
    
Oncology
    

ProTriTAC

EpCAM
GI Cancers
    
Oncology
    

TriTAC-XR

Oncology/Non-Oncology
    
Product Candidate
Target/Indication

For a description of our ongoing clinical studies, please visit clinicaltrials.gov.

For expanded access visit Expanded Access Policy.